A randomized, open-label study to compare the rate of new non-melanoma skin cancer in maintenance renal allograft recipients converted to a sirolimus-based regimen versus continuation of a calcineurin inhibitor-based regimen.

Trial Profile

A randomized, open-label study to compare the rate of new non-melanoma skin cancer in maintenance renal allograft recipients converted to a sirolimus-based regimen versus continuation of a calcineurin inhibitor-based regimen.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2012

At a glance

  • Drugs Ciclosporin; Sirolimus; Tacrolimus
  • Indications Basal cell cancer; Renal transplant rejection; Skin cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 22 Mar 2012 Status changed from active, no longer recruiting to completeds reported by ClinicalTrials.gov.
    • 22 Mar 2012 Company (Pfizer) added as trial sponsor as reported by ClinicalTrials.gov.
    • 30 Aug 2009 Results have been presented at the 14th Congress of the European Society for Organ Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top